Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Targeting GPA33 in Malignant Tumors
NCT07172503Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Open-label, single-arm trial of gallium-68 NOTA-GPA33 nanobody in colorectal cancer (CRC), gastric cancer (GC) and pancreatic cancer (PC). Primary endpoint: Visual and standardized uptake values assessment of lesions and biodistribution at 1 year. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
gallium-68 NOTA-GPA33 nanobody
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07172503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172503.